Literature DB >> 17203169

Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression.

Masanori Miyanishi1, Masaki Mandai, Noriomi Matsumura, Ken Yamaguchi, Junzo Hamanishi, Toshihiro Higuchi, Kenji Takakura, Shingo Fujii.   

Abstract

Malignant transformation is caused by multi-step genetic mutations, and growth factors are believed to play important roles in developing and maintaining malignant phenotype. However, there is no direct evidence that a specific growth factor contributes to malignant transformation of phenotypically normal cells. In order to assess the function of Acrogranin (also known as granulin epithelial precursor; GEP) in ovarian carcinogenesis, ovarian surface epithelial (OSE) cells, which are supposed to be the origin of primary ovarian epithelial cancer, were transfected with combined genes of hTERT, SV40 LT, and Acrogranin. Introduction of hTERT and SV40 LT was sufficient for immortalizing OSE cells but not enough for tumor formation in nude mice. In contrast, transfection and overexpression of Acrogranin in immortalized OSE cells showed augmented clonogenicity in soft agar and obvious tumorigenicity in nude mice. This is the first study showing evidence that a specific growth factor plays a direct role in malignant transformation in ovarian cancer development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17203169

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

Review 1.  Cellular effects of progranulin in health and disease.

Authors:  Louis De Muynck; Philip Van Damme
Journal:  J Mol Neurosci       Date:  2011-05-25       Impact factor: 3.444

Review 2.  Progranulin and its biological effects in cancer.

Authors:  Fabian Arechavaleta-Velasco; Carlos Eduardo Perez-Juarez; George L Gerton; Laura Diaz-Cueto
Journal:  Med Oncol       Date:  2017-11-07       Impact factor: 3.064

3.  Progranulin promotes colorectal cancer proliferation and angiogenesis through TNFR2/Akt and ERK signaling pathways.

Authors:  Dong Yang; Lin-Lin Wang; Tao-Tao Dong; Yi-Hang Shen; Xiao-Sun Guo; Chuan-Yong Liu; Jie Liu; Pei Zhang; Juan Li; Yu-Ping Sun
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

4.  Growing a tumor stroma: a role for granulin and the bone marrow.

Authors:  Andrew Bateman
Journal:  J Clin Invest       Date:  2011-01-25       Impact factor: 14.808

Review 5.  Structure, function, and mechanism of progranulin; the brain and beyond.

Authors:  Huishi Toh; Babykumari P Chitramuthu; Hugh P J Bennett; Andrew Bateman
Journal:  J Mol Neurosci       Date:  2011-06-21       Impact factor: 3.444

6.  Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.

Authors:  Jasmine J Han; Minshu Yu; Nicole Houston; Seth M Steinberg; Elise C Kohn
Journal:  Gynecol Oncol       Date:  2010-10-15       Impact factor: 5.482

7.  Overexpression of protease inhibitor-dead secretory leukocyte protease inhibitor causes more aggressive ovarian cancer in vitro and in vivo.

Authors:  Nick Devoogdt; Nabila Rasool; Ebony Hoskins; Fiona Simpkins; Nana Tchabo; Elise C Kohn
Journal:  Cancer Sci       Date:  2009-01-14       Impact factor: 6.716

Review 8.  Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration.

Authors:  Basar Cenik; Chantelle F Sephton; Bercin Kutluk Cenik; Joachim Herz; Gang Yu
Journal:  J Biol Chem       Date:  2012-08-02       Impact factor: 5.157

9.  The Evolution of the Secreted Regulatory Protein Progranulin.

Authors:  Roger G E Palfree; Hugh P J Bennett; Andrew Bateman
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

Review 10.  Mechanisms of Progranulin Action and Regulation in Genitourinary Cancers.

Authors:  Ryuta Tanimoto; Kuojung G Lu; Shi-Qiong Xu; Simone Buraschi; Antonino Belfiore; Renato V Iozzo; Andrea Morrione
Journal:  Front Endocrinol (Lausanne)       Date:  2016-07-27       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.